Current Research Studies

Cancer – SC-4009: A Phase 2 Study of Therapeutic Iobenguane (131-I) for Relapsed, High-Risk Neuroblastoma Subjects (OPTIMUM)

Condition or Therapy:



Cancer and Blood Disorders
Study Number: SC-4009

What is the goal of this study?

The purpose of this study is to evaluate the efficacy and safety of 131I-MIBG in patients with neuroblastoma who have relapsed.

Who can join the study?

This study may be a good fit for children and young adults who:

  • Are age 1 older, and 
  • Have a diagnosis of iobenguane avid, relapsed, high-risk neuroblastoma based on revised INRC criteria who have completed at least one cycle of induction and consolidation therapy with an INRC criterion of partial response or better, and then showed new progressive disease

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Navin Pinto
Research Center: Center for Clinical and Translational Research